Trubion Pharmaceuticals announced the initiation of a Phase 2 trial of SBI-087 for the treatment of rheumatoid arthritis (RA). This trial is a multi-center, randomized, placebo-controlled, double-blind, parallel-group, outpatient dose regimen-finding study initiated by Trubion’s collaboration partner, Pfizer. Patients enrolled in this study will meet the criteria for RA with American College of Rheumatology (ACR) Functional class I, II or III, are seropositive, and will have been diagnosed with RA more than six months before trial initiation. Participants will be randomly assigned to receive either placebo or one of four SBI-087 dosing regimens. This study is designed to evaluate the safety and efficacy of a dose and dosage regimen of SBI-087 in seropositive patients with active RA, who are on a stable dose of methotrexate. The primary outcome measure will include responses based on the ACR criteria (ACR 20 response).
SBI-087 is a next-generation, humanized Small Modular ImmunoPharmaceutical (SMIP) protein therapeutic directed against the CD20 antigen.
For more information call (206) 838-0500 or visit www.trubion.com.